ARDELYX, INC. Proceeds from Maturities, Prepayments and Calls of Short-term Investments
ARDELYX, INC. (ARDX) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $114.48 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2019-11-06
- ARDELYX, INC. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2019-09-30 was $28.03M, a 28.86% decline year-over-year.
- ARDELYX, INC. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2019-06-30 was $31.43M, a 65.75% increase year-over-year.
- ARDELYX, INC. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2019-03-31 was $55.02M, a 48.36% increase year-over-year.
- ARDELYX, INC. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2018-09-30 was $39.40M, a 14.24% increase year-over-year.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month |
|---|---|---|---|
| 2019-09-30 | $28.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $59.46M derived: sum of 2 quarters · filed 2019-11-06 | $114.48M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $31.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $86.45M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $55.02M 10-Q · filed 2019-05-07 | ||
| 2018-09-30 | $39.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $58.37M derived: sum of 2 quarters · filed 2019-11-06 | $95.45M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $18.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $56.05M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $37.09M 10-Q · filed 2019-05-07 | ||
| 2017-09-30 | $34.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $78.05M derived: sum of 2 quarters · filed 2018-11-07 | $109.92M 10-Q · filed 2018-11-07 |
| 2017-06-30 | $43.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $75.43M 10-Q · filed 2018-08-07 | |
| 2017-03-31 | $31.87M 10-Q · filed 2018-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |